Latest News
-
Monday - July 26, 2021
BlueRock Therapeutics Announces New Board Chair, New President and CEO » more
-
Monday - July 26, 2021
Bayer announces Prof. Dr. Dominik Ruettinger as new Head of Research and Early Development for Oncology » more
-
Wednesday - July 21, 2021
Bayer Reinforces Commitment to Increasing Fruit and Vegetable Consumption
Commitment to promoting increased fruit and vegetable consumption key to Bayer’s vision of ‘Health for All, Hunger for None’ / Portfolio innovations and Field-to-Fork Horticulture strategy put digital transformation and innovation at the core of Bayer’s fruit and vegetable offerings / Bayer is now a participating member of the Sustainability Initiative for Fruits and Vegetables (SIFAV) » more
-
Wednesday - July 21, 2021
Not intended for U.S. and UK Media
Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU
Approved for adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous therapy / Studied in a population with a high risk of cardiovascular death or heart failure hospitalization / The sGC-stimulator Verquvo provides a specific approach to managing chronic heart failure following a decompensation event » more
-
Monday - July 19, 2021
BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson’s Disease » more
-
Friday - July 9, 2021
Not intended for U.S. and UK Media
U.S. FDA approves finerenone for the treatment of patients with chronic kidney disease associated with type 2 diabetes
Finerenone is the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate positive kidney and cardiovascular outcomes in patients with chronic kidney disease associated with type 2 diabetes / Despite guideline-directed therapies, many patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) still progress to loss of kidney function and are at high risk for cardiovascular events / By blocking MR overactivation, a key driver of CKD progression, finerenone works on a pathway largely unaddressed by existing treatments for CKD in T2D » more
-
Thursday - July 1, 2021
Solvay completes acquisition of Bayer’s global seed coatings business
The acquisition strengthens Solvay's existing seed care portfolio in bio-based, seed-applied solutions; enables reinvestment opportunities for Bayer » more
-
Thursday - July 1, 2021
Bayer opens application window for Grants4Ag sustainability-focused program
Program awards researchers and scientists for sustainable solutions to agricultural challenges / Selected grant winners receive both financial prize and mentorship from industry leaders » more
-
Tuesday - June 29, 2021
Bayer Carbon Initiative:
Bayer launches its decarbonization program for agriculture in Europe
In line with the political objectives of the EU Green Deal, the program’s main goal is to fight climate change by establishing carbon farming practices at farmers’ level with benefits for the entire agricultural value chain / Program kicks off with over 25 farmers across seven countries in the EU and beyond: France, Spain, Belgium, Denmark, Germany, United Kingdom and Ukraine » more
-
Wednesday - June 23, 2021
Not intended for U.S. and UK Media
Rivaroxaban application submitted to U.S. FDA for approval to treat VTE and to prevent VTE in children
Application seeks two pediatric indications, including an age-appropriate new weight-based oral suspension formulation / If approved, Xarelto™ (rivaroxaban) will be the only oral Factor Xa Inhibitor indicated in the U.S. for use in appropriate pediatric patients » more
-
Wednesday - June 23, 2021
Not intended for U.S. and UK Media
Vericiguat approved in Japan to treat patients with chronic heart failure
Heart failure affects approximately 1.2 million people in Japan » more
-
Monday - June 21, 2021
Not intended for U.S. and UK Media
Bayer submits regulatory applications for oncology treatment combination of copanlisib and rituximab in the U.S. and EU
In the US, Bayer has filed for relapsed indolent B-cell non-Hodgkin’s lymphoma (B-iNHL) / In the EU, Bayer has filed for relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted / Filings based on results from Phase III trial CHRONOS-3 showing a significant improvement in the primary endpoint of progression-free survival for the combination of copanlisib and rituximab in patients with relapsed iNHL » more
-
Tuesday - June 8, 2021
Bayer to advance two first-of-its-kind cell and gene therapies for Parkinson’s disease
Parkinson’s disease is most common neurodegenerative movement disorder / It impacts more than 10 million people worldwide/ No function-restoring therapy is currently available / Bayer is pursuing a two-pronged approach to deliver transformative therapies with one cell and one gene therapy candidate in clinical trials » more
-
Thursday - June 3, 2021
Not intended for U.S. and UK Media
Bayer acquires Noria and PSMA Therapeutics to expand portfolio in prostate cancer
Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer » more
-
Wednesday - June 2, 2021
Researchers with unique ideas on helping farmers protect their crops selected as Bayer 2021 Grants4Ag awardees
24 scientists will receive both financial and scientific support for their crop science research proposal / Successful projects have the potential to become future collaborations with Bayer / Researchers selected from more than 600 proposals representing 39 countries » more
-
Thursday - May 27, 2021
Leaps by Bayer leads USD 90 Million Series B financing in digital health company Ada Health
Ada Health combines medical knowledge with powerful AI to revolutionize possibilities for personal health for patients globally / Investment to support advancement of Ada’s symptom assessment and care navigation platform » more
-
Thursday - May 27, 2021
Conference Call for investors and media
Address by Werner Baumann
Chairman of the Board of Management » more
-
Thursday - May 27, 2021
Bayer announces five-point plan to effectively address potential future Roundup™ claims » more
-
Wednesday - May 26, 2021
Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine
Collaboration combines BlueRock’s leading induced pluripotent stem cell (iPSC) platform technology and genome biology expertise with Senti Bio’s proprietary gene circuit technology platform, including Smart Sensors and Regulator Dials » more
-
Tuesday - May 25, 2021
AskBio Announces IND for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), Cleared to Proceed by U.S. FDA
LGMD2I/R9 is a Rare Form of Muscular Dystrophy with No Approved Therapies / First-in-Human Phase 1/2 Clinical Study Expected to Begin Dosing in 1H 2022 » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Thursday, August 5, 2021
Half-Year Report 2021
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV